Video

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Author(s):

John Heymach, MD, PhD, MD Anderson Cancer Center

In Partnership With:

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Related Videos
Phase 3 AMPLIFY Trial
Nazli Dizman, MD
Hidehito Horinouchi, MD, PhD
Guillermo Garcia-Manero, MD
RLY-2608
Ewa Kalinka, MD, PhD
BOVen
Related Content
Zipalertinib in Pretreated EGFR-Mutant NSCLC | Image Credit: © catalin – stock.adobe.com
January 29th 2025

REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Alexander Watson, MD, DPhil, FRCPC, of University of Colorado Denver
January 28th 2025

Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

TKIs in Second-Line HER2-Mutant NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting